Stockscreener 앱 받기
4.60
1.32%
0.06
시간 외 거래:
4.59
-0.010
-0.22%
전일 마감가:
$4.54
열려 있는:
$4.45
하루 거래량:
71,949
Relative Volume:
0.05
시가총액:
$24.74M
수익:
$15.66M
순이익/손실:
$5.83M
주가수익비율:
-0.1925
EPS:
-23.8939
순현금흐름:
$466.20K
1주 성능:
+5.26%
1개월 성능:
+12.20%
6개월 성능:
-32.55%
1년 성능:
+0.00%
1일 변동 폭
$4.37
$4.65
1주일 범위
$4.10
$4.65
52주 변동 폭
$2.90
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
명칭
Neuphoria Therapeutics Inc
전화
781-439-5551
주소
100 SUMMIT DR, BURLINGTON
NEUP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
4.60 | 24.41M | 15.66M | 5.83M | 466.20K | -23.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.01 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
692.58 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
415.21 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.41 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.17 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | 재확인 | Maxim Group | Buy |
| 2022-01-10 | 개시 | Berenberg | Buy |
| 2022-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-01-10 | 개시 | Evercore ISI | Outperform |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
모두보기
Neuphoria Therapeutics Inc 주식(NEUP)의 최신 뉴스
Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees - Yahoo Finance
ISS recommends shareholders vote for Neuphoria’s board nominees By Investing.com - Investing.com India
Institutional Shareholder Services Recommends Shareholders of Neuphoria to Vote for its Director Nominees - marketscreener.com
ISS recommends shareholders vote for Neuphoria’s board nominees - Investing.com
Neuphoria Therapeutics (NEUP) Gains ISS Support for Director Nom - GuruFocus
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees - The Manila Times
Leading Proxy Advisory Firm ISS Recommends that - GlobeNewswire
HC Wainwright Has Lowered Expectations for Neuphoria Therapeutics (NASDAQ:NEUP) Stock Price - Defense World
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA) - The Globe and Mail
Neuphoria Therapeutics (NEUP) Stock Analysis Report | Financials & Insights - Benzinga
HC Wainwright & Co. Maintains Neuphoria Therapeutics (NEUP) Buy Recommendation - Nasdaq
NEUP: Analyst Lowers Price Target by 66% but Maintains 'Buy' Rat - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer By Investing.com - Investing.com Nigeria
Will Neuphoria Therapeutics Inc. stock deliver strong dividend growthIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Neuphoria Therapeutics (NEUP) Considers Strategic Alternatives A - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer - Investing.com
Neuphoria responds to Lynx1's revised indication of interest at a reduced price and premium - marketscreener.com
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium - The Manila Times
Is Neuphoria Therapeutics Inc. stock near bottom after declineEarnings Risk Report & Weekly Top Stock Performers List - Newser
Lynx1 Master Sends a Letter to the Shareholders of Neuphoria Therapeutics - marketscreener.com
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders - Yahoo Finance
Lynx1 Master Fund Critiques Neuphoria Therapeutics Inc. Board's Capital-Raising Strategy and Proposes Independent Director Nominees in Proxy Statement - marketscreener.com
Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program - MSN
Neuphoria responds to Lynx1’s proxy contest claims in board dispute By Investing.com - Investing.com Australia
Neuphoria Therapeutics (NEUP) Encourages Shareholders to Support Its Nominees - GuruFocus
Neuphoria responds to Lynx1’s proxy contest claims in board dispute - Investing.com
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions - marketscreener.com
Neuphoria Therapeutics downgraded to Neutral from Buy at Lucid Capital - MSN
Reviewing Neuphoria Therapeutics (NEUP) & The Competition - Defense World
What analysts say about Neuphoria Therapeutics Inc stockMACD Histogram Signals & Discover Your Financial Freedom Formula - earlytimes.in
Sell Signal: How Neuphoria Therapeutics Inc. stock reacts to global recession fearsSwing Trade & Free AI Powered Buy and Sell Recommendations - moha.gov.vn
Lynx1 Capital Management Solicits Proxies from Shareholders of Neuphoria Therapeutics - marketscreener.com
Neuphoria urges stockholders to vote for its nominees amid strategic review - Investing.com Nigeria
Neuphoria Therapeutics Sends Letter to Stockholders - marketscreener.com
Neuphoria Therapeutics (NEUP) Outlines Strategic Review Ahead of Annual Meeting - GuruFocus
Making the Most of Varied Backgrounds: Ogunbufunmi’s Bold Move Toward Technology Leadership - Bitget
Neuphoria urges stockholders to vote for its nominees amid strategic review By Investing.com - Investing.com South Africa
Neuphoria Therapeutics Inc. Sends Letter to Stockholders - Yahoo Finance
Why Did NEUP Stock Surge 64% Today? - MSN
What drives Neuphoria Therapeutics Inc stock priceStop Loss Placement Tips & Small Budget Growth - earlytimes.in
Tenax Therapeutics, Inc. (TENX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
How supply chain issues affect Neuphoria Therapeutics Inc. stock2025 Major Catalysts & Fast Entry and Exit Trade Plans - newser.com
Will Neuphoria Therapeutics Inc. stock continue upward momentumMarket Movement Recap & Daily Oversold Stock Bounce Ideas - newser.com
What does recent volatility data suggest for Neuphoria Therapeutics Inc.2025 Earnings Impact & Weekly Market Pulse Updates - newser.com
Neuphoria Therapeutics Inc (NEUP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.50%
자본화:
|
볼륨(24시간):